Sorafenib, sunitinib, and pazopanib

Sorafenib, sunitinib, and pazopanib are small molecules that inhibit multiple receptor tyrosine kinases (RTKs), including those associated with the VEGF receptor family. They are metabolized by CYP3A4, and elimination is primarily hepatic. Hypertension, bleeding complications, and fatigue are the most common adverse effects.